CRISPR Therapeutics AG SEC filings CRSP
CRISPR Therapeutics AG has 880 filings in SEC EDGAR's recent list, going back to May 13, 2016. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 21, 2026 | — |
| DEF 14A | Proxy statement | Apr 21, 2026 | Jun 4, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2026 | Jun 4, 2026 |
| DEFA14A | Additional proxy material | Apr 16, 2025 | — |
| DEF 14A | Proxy statement | Apr 16, 2025 | Jun 5, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2025 | Jun 5, 2025 |
| DEFA14A | Additional proxy material | Apr 9, 2024 | — |
| DEF 14A | Proxy statement | Apr 9, 2024 | May 30, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2024 | May 30, 2024 |
| DEFA14A | Additional proxy material | May 18, 2023 | — |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 10, 2023 | — |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 9, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2022 | Jun 9, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2021 | — |
| DEF 14A | Proxy statement | Apr 28, 2021 | Jun 10, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2021 | Jun 10, 2021 |
| DEFA14A | Additional proxy material | May 15, 2020 | — |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEF 14A | Proxy statement | Apr 24, 2020 | Jun 11, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2020 | Jun 11, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 11, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 9, 2019 | Jun 11, 2019 |
| DEFA14A | Additional proxy material | Apr 18, 2018 | — |
| DEF 14A | Proxy statement | Apr 18, 2018 | May 30, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2018 | May 30, 2017 |
| DEFA14A | Additional proxy material | Apr 18, 2017 | — |
| DEF 14A | Proxy statement | Apr 18, 2017 | May 31, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2017 | May 31, 2017 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zug
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1674416
- Former names
- CRISPR Therapeutics AG (until Nov 2, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.